마시티닙

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Pregnant or lactating bitches
• Dogs < 24 months old
• Dogs < 7 kg body weight
• Pre-existing signs of myelosuppression
• Previous hypersensitivity to masitinib

이상반응

• Diarrhoea (mild to moderate)
• Vomiting (mild to moderate)
• Hair coat changes or alopecia
• Renal toxicity
• Anaemia
• Protein loss (protein-losing nephropathy/enteropathy)
• Myelosuppression
• Increased liver enzyme activity
• Lethargy
• Cough
• Lymphadenomegaly

약물 상호작용

• Highly protein-bound drugs · May displace masitinib or be displaced, increasing the risk of adverse side effects · moderate
• Cytochrome P450 inhibitors or inducers · May alter the metabolism of masitinib, increasing the risk of toxicity or reducing efficacy · moderate

모니터링

• Blood pressure (baseline and monthly)
• Urinalysis (baseline and monthly)
• Haematology (baseline and monthly)
• Biochemistry (baseline and monthly)
• Coagulation profiles (if adverse signs witnessed)
• Faecal occult blood tests (if adverse signs witnessed)
• Weekly owner check-ins for the first 6 weeks to monitor for side effects

과용량

No specific overdose information is provided in the monograph. > **Clinical Pearl:** Overdose of tyrosine kinase inhibitors typically exacerbates gastrointestinal toxicity (severe vomiting, diarrhea) and myelosuppression. Treatment is symptomatic and supportive. Monitor renal and hepatic parameters closely.